Clicky

Jiangsu Sihuan Bioengineering Co Ltd(000518)

Description: Jiangsu Sihuan Bioengineering Co., Ltd. engages in the pharmaceutical business in China. It offers Drewson, an anti-tumor biotherapeutic drug for the treatment of renal cancer, malignant melanoma, and cancerous thoracic and peritoneal effusion; and Xinde Lusheng for the treatment of kidney cancer, melanoma, lung cancer, gastric cancer, malignant lymphoma, breast cancer, ovarian tumor, bowel cancer, bladder cancer, head and neck tumor, leukemia and cancerous pleural effusion, etc. The company also provides Xin grain health, a recombinant human granulocyte colony stimulating factor injection; and Tourbo, a recombinant human erythropoietin injection for the treatment of anemia caused by renal insufficiency, including dialysis and non-dialysis patients. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.


Keywords: Medicine Pharmaceutical Cancer Oncology Breast Cancer Dialysis Lung Cancer Melanoma Ovarian Cancer Leukemia Anemia Bladder Cancer Gastric Cancer Renal Cancer Malignant Lymphoma Treatment Of Renal Cancer Bowel Cancer Kidney Cancer Malignant Melanoma Pleural Cavity Treatment Of Kidney Cancer

Home Page: www.000518shsw.com/shsw

No. 7 Binjiang East Road
Jiangyin, 214400
China
Phone: 86 510 8640 8558


Officers

Name Title
Mr. Yu Guo GM & Chairman
Ms. Haizhen Xu CFO & Head of Accounting
Mr. Yang Zhou Sec. of the Board & Deputy GM

Exchange: SHE

Country: CN

Currency: Renminbi (¥)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 6.4587
Price-to-Sales TTM: 11.7709
IPO Date: 1993-04-26
Fiscal Year End: December
Full Time Employees: 254
Back to stocks